BAT 3306
Alternative Names: BAT-3306Latest Information Update: 31 Jul 2024
Price :
$50 *
At a glance
- Originator Bio-Thera Solutions
- Class Antineoplastics; Monoclonal antibodies; Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 25 Jul 2024 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, First-line therapy) in China (IV) prior to July 2024 (NCT06280196)
- 04 Mar 2024 Bio-Thera Solutions plans a phase I/III trial for Non-small cell lung cancer (Combination-therapy, Late-stage disease, First line therapy) in August 2024 (IV) (NCT06280196)
- 01 Nov 2023 Preclinical trials in Cancer in China (IV, Injection)